Picture loading failed.

Anti-CLEC12A;CD3E therapeutic antibody (Pre-made Tepoditamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tepoditamab (formerly MCLA 117) a bispecific, human IgG antibody (with a silenced region), is being developed by Merus for the treatment of acute myeloid.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-563-1mg 1mg 3090
GMP-Bios-ab-563-10mg 10mg 21890
GMP-Bios-ab-563-100mg 100mg 148000
GMP-Bios-ab-563-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CLEC12A;CD3E therapeutic antibody (Pre-made Tepoditamab biosimilar,Bispecific mAb)
INN Name Tepoditamab
TargetCLEC12A;CD3E
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesGenmab;Janssen Research & Development
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Myelodysplastic syndromes
Conditions Discontinuedna
Development Techna